Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

@article{Demetri2012CompleteLA,
  title={Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.},
  author={George Daniel Demetri and Christopher R. Garrett and Patrick Sch{\"o}ffski and Manisha Hasmukhray Shah and Jaap Verweij and Serge Leyvraz and Herbert I. Hurwitz and Antonio L{\'o}pez Pousa and Axel L E Cesne and David Goldstein and Luis Paz-Ares and Jean-Yves Blay and Grant Mcarthur and Qiang Casey Xu and Xin Huang and Charles S. Harmon and Vanessa Tassell and Darrel P. Cohen and Paolo Giovanni Casali},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2012},
  volume={18 11},
  pages={3170-9}
}
PURPOSE To analyze final long-term survival and clinical outcomes from the randomized phase III study of sunitinib in gastrointestinal stromal tumor patients after imatinib failure; to assess correlative angiogenesis biomarkers with patient outcomes. EXPERIMENTAL DESIGN Blinded sunitinib or placebo was given daily on a 4-week-on/2-week-off treatment schedule. Placebo-assigned patients could cross over to sunitinib at disease progression/study unblinding. Overall survival (OS) was analyzed… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

  • GD Demetri, AT van Oosterom, CR Garrett, ME Blackstein, MH Shah, J Verweij
  • Lancet
  • 2006
Highly Influential
20 Excerpts

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

  • HeinrichMC, RG Maki, CorlessCL, AntonescuCR, HarlowA, GriffithD
  • J Clin Oncol 2008;26:5352–9
  • 2012
Highly Influential
13 Excerpts

Correcting for non-compliance in randomized trials using rank-preserving structural failure time models

  • JM Robins, A. Tsiatis
  • Commun Stat Theory Methods
  • 1991
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…